{"id":5361,"date":"2026-07-09T16:14:15","date_gmt":"2026-07-09T20:14:15","guid":{"rendered":"https:\/\/test-arcutis-canada.pantheonsite.io\/?p=5361"},"modified":"2026-08-20T13:08:32","modified_gmt":"2026-08-20T17:08:32","slug":"arcutis-canada-repond-aux-recommandations-dorganismes-devaluation-des-technologies-de-la-sante-ets-influencant-lacces-des-patients-a-la-creme-%e1%b4%be%ca%b3zoryve-a","status":"publish","type":"post","link":"https:\/\/www.arcutis.ca\/fr\/arcutis-canada-repond-aux-recommandations-dorganismes-devaluation-des-technologies-de-la-sante-ets-influencant-lacces-des-patients-a-la-creme-%e1%b4%be%ca%b3zoryve-a\/","title":{"rendered":"Arcutis Canada r\u00e9pond aux recommandations d\u2019organismes d\u2019\u00e9valuation des technologies de la sant\u00e9 (ETS) influen\u00e7ant l\u2019acc\u00e8s des patients \u00e0 la cr\u00e8me \u1d3e\u02b3ZORYVE\u00ae \u00e0 0,15\u00a0% pour le traitement de la dermatite atopique"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>CDA-AMC and INESSS recommend against public reimbursement for ZORYVE cream 0.15%<\/li>\n\n\n\n<li>HTA recommendations leave patients dependent on public drug plans facing barriers to accessing a once-daily, steroid-free topical suitable for long-term use<\/li>\n\n\n\n<li>Atopic dermatitis, the most prevalent form of eczema, is a chronic inflammatory condition marked by intense itch and inflammation, with impacts that extend well beyond the skin<\/li>\n<\/ul>\n\n<p class=\"wp-block-paragraph\"><strong>TORONTO, ON, July 9, 2026 \u2013 <\/strong>Arcutis Canada, Inc., a commercial stage company focused on delivering meaningful innovations in immunodermatology, is raising concerns about recent reimbursement recommendations from Canada\u2019s Drug Agency (CDA-AMC) and Quebec\u2019s Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS) for <sup>Pr<\/sup>ZORYVE<sup>\u00ae<\/sup> (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis for patients 6 years of age and older.<\/p>\n\n<p class=\"wp-block-paragraph\">The recommendations against publicly reimbursing ZORYVE will impact access for Canadians relying on public drug plans. They also highlight broader gaps in access to newer, steroid-free treatment options, contributing to widening disparities between therapies approved by Health Canada, therapies reimbursed by private insurers and those accessible through publicly funded programs.<\/p>\n\n<p class=\"wp-block-paragraph\">Positive reimbursement recommendations are an important step toward improving access to innovative therapies. In this context, the recommendations for ZORYVE reinforce the current public care pathway where many Canadians living with atopic dermatitis requiring treatment will need to continue to resort to outdated therapies despite evolving clinical practice and newer treatment options. The CDA-AMC and INESSS recommendations also appear at odds with growing recognition of limitations associated with long-term reliance on topical corticosteroids. This includes a Health Canada safety reminder about rare but severe topical corticosteroid withdrawal reactions which may occur upon discontinuation after prolonged and\/or inappropriate use of mostly moderate to high potency topical steroids.<\/p>\n\n<p class=\"wp-block-paragraph\">\u201cJust because atopic dermatitis can be mild to moderate, this does not mean that this disease does not have significant impact on patients\u2019 lives and on their caregivers. It can be challenging to manage atopic dermatitis when we have very few non-steroidal options for patients who do not have private coverage to access the newer,\u00a0effective medications that may be appropriate for their individual needs,\u201d said Toronto-based dermatologist, Dr. Perla Lansang. \u201cTopical steroids have their limitations, and the publicly funded non-steroidal options are sometimes not suitable for all patients. More recent therapies like\u00a0ZORYVE are supported by clinical evidence\u00a0and expand the range of treatment options available for chronic diseases that need long-term management. Ensuring that all patients, not only those with private coverage, can access these medications is so important.\u201d<\/p>\n\n<p class=\"wp-block-paragraph\">In addressing the burden of atopic dermatitis, many patients remain limited to steroid-based topical therapies that have long played an important role in disease management but may present considerations related to sustained use or use on certain areas of the body. In long-term use, topical corticosteroids may be associated with side effects, including skin atrophy, discoloration, and stria. In addition, treatment regimens for atopic dermatitis using older, established options often require the use of multiple topical therapies with different formulations and application schedules, which can be complex, time-consuming, and difficult to maintain consistently.<\/p>\n\n<p class=\"wp-block-paragraph\">Patients who are unable to achieve adequate disease control with topical therapies are often escalated to more complex and higher-cost treatment options, including phototherapy, systemic therapies, or biologics\u2014approaches that may require ongoing monitoring, additional healthcare resources, and can place greater burden on patients, caregivers, and the healthcare system.<\/p>\n\n<p class=\"wp-block-paragraph\">\u201cAdvancing innovation for Canadians living with chronic skin conditions\u00a0is a\u00a0core focus for Arcutis, particularly as symptoms can affect daily comfort, confidence and quality of life,\u201d said Jamie Lewis, Vice President &amp; General Manager, Arcutis Canada. \u201cArcutis remains committed to delivering needed therapies to help address the\u00a0real-world impact and ongoing burden of dermatological conditions\u00a0such as atopic dermatitis\u00a0while\u00a0also supporting healthcare providers in the management of these complex conditions.\u201d<\/p>\n\n<p class=\"wp-block-paragraph\">Atopic dermatitis is a chronic, inflammatory disease characterized by persistent, unpredictable, and often debilitating itch with recurrent flares that can significantly disrupt sleep, impair daily functioning, and affect emotional well-being and quality of life.<\/p>\n\n<p class=\"wp-block-paragraph\">\u00ab\u00a0As\u00a0the most common form of eczema,\u00a0atopic dermatitis\u00a0is\u00a0a challenging\u00a0chronic condition\u00a0to live with, and the itch, pain,\u00a0and\u00a0visible symptoms\u00a0can impact\u00a0quality of\u00a0life for patients and caregivers,\u201d\u00a0said Amanda Cresswell-Melville, Executive Director of the\u202fEczema Society of Canada.\u00a0\u201cCanadian eczema patients continue to face unmet treatment needs to manage this complex condition. Unfortunately,\u00a0managing\u00a0atopic dermatitis can be very difficult, and\u00a0it is frustrating\u00a0to see\u00a0reimbursement decisions\u00a0that minimize\u00a0the effect\u00a0this condition\u00a0can have\u00a0on\u00a0daily\u00a0life, including disruptive itch,\u00a0loss of\u00a0sleep, and\u00a0missed\u00a0work and\u00a0school.\u00a0\u00bb<\/p>\n\n<p class=\"wp-block-paragraph\">ZORYVE is a selective phosphodiesterase\u20114 (PDE4) inhibitor available in multiple topical formulations in approved in Canada for topical dermatological use. ZORYVE cream 0.15% is approved by Health Canada for the treatment of mild to moderate atopic dermatitis in individuals 6 years of age and older.<\/p>\n\n<p class=\"wp-block-paragraph\">ZORYVE cream and foam formulations are not\u00a0currently reimbursed under public drug plans in Canada, though patients may be eligible for coverage through private insurance plans. Arcutis Canada will continue to engage with federal, provincial, and territorial stakeholders, as well as the clinical and patient communities, to advance understanding of the unmet patient needs and explore pathways to support public reimbursement and equitable access for Canadians.<\/p>\n\n<p class=\"wp-block-paragraph\">Please consult the Canadian product monograph\u00a0<a href=\"https:\/\/www.arcutis.ca\/zoryve-pm-hcp\">here<\/a> for complete prescribing and safety information.<\/p>\n\n<p class=\"wp-block-paragraph\"><strong>About Arcutis\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong>           <\/p>\n\n<p class=\"wp-block-paragraph\">Arcutis Canada, Inc. is a subsidiary of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis\u2019 unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit\u00a0<a href=\"http:\/\/www.arcutis.ca\/\">www.arcutis.ca<\/a>.<\/p>\n\n<p class=\"wp-block-paragraph\"><strong>Contacts:<\/strong><\/p>\n\n<p class=\"wp-block-paragraph\"><em><u>Media<\/u><\/em><br\/>Amanda Sheldon, Head of Corporate Communications<br\/><a href=\"mailto:media@arcutis.com\">media@arcutis.com<\/a><\/p>\n\n<p class=\"wp-block-paragraph\"><em><u>Investors<\/u><\/em><br\/>Brian Schoelkopf, Head of Investor Relations<\/p>\n\n<p class=\"wp-block-paragraph\"><a href=\"mailto:ir@arcutis.com\">ir@arcutis.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"TORONTO, ON, July 9, 2026 \u2013 Arcutis Canada, Inc., a commercial stage company focused on [&hellip;]","protected":false},"author":21,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"4576,5017,4273,5312,5237,5186","_relevanssi_noindex_reason":"","inline_featured_image":false,"footnotes":""},"categories":[32],"tags":[],"pd_condition":[],"class_list":["post-5361","post","type-post","status-publish","format-standard","hentry","category-non-classifiee"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/posts\/5361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/users\/21"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/comments?post=5361"}],"version-history":[{"count":3,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/posts\/5361\/revisions"}],"predecessor-version":[{"id":5426,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/posts\/5361\/revisions\/5426"}],"wp:attachment":[{"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/media?parent=5361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/categories?post=5361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/tags?post=5361"},{"taxonomy":"pd_condition","embeddable":true,"href":"https:\/\/www.arcutis.ca\/fr\/wp-json\/wp\/v2\/pd_condition?post=5361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}